Marco Raddi

Landmark Paper: in 2002 Silverman et al. published results of the phase III CALGB 9221 trial, showing how azacitidine not only caused sustained improvement in cytopenias but also altered the course of myelodysplastic syndromes. haematologica.org/article/view/1…

Excellent discussions at the 4th annual i4MDS meeting in Milan — advancing immunobiology insights and moving closer to smarter stratification and better treatments for MDS. #i4MDS #EHA #MDS #Hematology #Immunology

Finally out! Imetelstat changes the game in LR-MDS by: → Shrinking the MDS clone → Reducing erythroid dysplasia → Restoring normal erythropoiesis A true paradigm shift — treating disease biology. #MDSs #anemia ⁦@Santin13Valeria⁩ nature.com/articles/s4137…

If you are interested in how to use molecular information for treatment response in LR-MDS, here I discuss our recent work. Check it out! vumedi.com/video/low-risk… via @vumedi

Thanks for sharing @FabioTorressav !! Optimize selection is key in treating LR-MDS anemia

A nice presentation by Marco Raddy about the selection of patients for ESA therapy @Mohty_EBMT @UsuarezMD @TheIACH

It’s finally out! Big thanks to all the collaborators who joined this project which will hopefully open the doors to a more personalized medicine for patients with LR-MDS based on gender and genetic profile. A special thank to my mentor @Santin13Valeria sciencedirect.com/science/articl…

⏰ 𝗧𝗵𝗲 𝗜𝗔𝗖𝗛 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗱𝗮𝘆𝘀 𝗮𝗿𝗲 𝗷𝘂𝘀𝘁 𝗮𝗿𝗼𝘂𝗻𝗱 𝘁𝗵𝗲 𝗰𝗼𝗿𝗻𝗲𝗿! Explore the exciting program & faculty: iach.cme-congresses.com/program/ 📅 October 9–11, 2025 Join us in Paris or online! @Mohty_EBMT @doctorpemm @nagler_EBMT @Santin13Valeria @Dr_AmerZeidan @MediHumdani @StefanoLuminari @AnnaSureda5 @harrisoncn1 @mpdrc #IACH #Hematology #Myeloma #Lymphoma #MPN #CellTherapy #StemCellTransplant

IACH News of the week 7 July, 2025 • @Mohty_EBMT @TheIACH Topics: - Allo-HCT in PTCL: guidelines @TheLancetHaem @TheEBMT - # TET2 mut. and CMML @LeukemiaJnl - IPSS-M risk, ESA, and LR-MDS @BloodPortfolio - BELLINI trial (RRMM) @TheLancetHaem iach.org/news-of-the-we…

Plenary session on low risk MDS treatment from MDS foundation congress. As last speaker I will share some data from our group @Santin13Valeria uncovering “dark” aspects of ring sideroblasts presence in MDS with low blasts count! youtu.be/ILWWorQBdp0?si…

Want a comprehensive overview of the current treatment options for patients with lower-risk MDS and anemia?🩸 Then don't forget to check out our fantastic interview with @Santin13Valeria (@UNI_FIRENZE) from #EHA2025!😄 Watch here: 🎥 ow.ly/uvtC50WfVHv #MDSsm #HemOnc

@Wang_Yu_Hung Thanks 😊

@le_markg Big congrats!!

It’s finally out in Blood!! A new molecular scoring system improving ESA response prediction in LR-MDS (ESA-PSS-M). Check it out! Thanks to all the collaborators #precisionmedicine #MDS ashpublications.org/blood/article-…

It’s out! Honored to have contributed with my mentor to this comprehensive and practical review on newly approved treatments for LR-MDS! American Society of Clinical Oncology Educational Book ascopubs.org/doi/10.1200/ED…

Hope to see you tomorrow at #MDS2025 in the beautiful #Rotterdam! An unique opportunity to explore the forefront of Myelodysplastic Syndromes! If you have intereset in MDS-RS biology and clinical correlations, join the session below! "invt.io/1txbc4y8r2h".

@sanamloghavi Many thanks @sanamloghavi!

@le_markg Congratulations, Marco!!

It’s such a great honor that my work has been awarded the second prize for clinical research at #U40inhematology It was such a pleasure to join this project and see young colleagues and friends from every part of Italy to present and discuss research in hematology.

@CollaSimona Thanks for the follow Simona 🙂 so nice meeting you in person! And don’t worry I’m not such a twitter guy my self, hope to see you soon!!

@le_markg I am not a Twitter person. Still can not get how twitter works. I am stupid. Sorry. But Marco!!!!! Great job so nice to meet you.

In past 2 days, we had our annual #i4MDS meeting in The Hague. Great discussions with colleagues about the role of the immune system in MDS and novel findings. Three years ago, when we founded this group, I never expected this level of progress and collaboration. Truly delighted.